It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
It is always interesting to see what analysts believe the big new drugs of the year are going to be worth 5 years down the road and Clarivate Analytics has listed the 9 blockbusters their analysts expect to see approved by the FDA this year.
Merck wanted to state on the label of their diabetes drug Januvia that patients could take it without raising their risk for cardio complications to distinguish themselves from same-class rivals like Onglyza, which has risks. FDA has nixed the idea.
AstraZeneca plc disclosed Friday via its official WeChat account that a key lung cancer drug has received approval from Chinese regulators, opening up a potentially very lucrative new market in a country where millions suffer from the disease.
AstraZeneca & Valeant have been battling it out in the opioid-induced constipation arena with movantik and relistor, respectively, since winning their FDA approvals back in September 2014. Now there’s a third competitor prepping to jump into the mix.
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
I hope my screed last week about frothy dry bulk carrier stocks persuaded you not to get into that thicket—or to sell out if you had been lured in. The group, led by Dryships, which we sold ages ago, duly crashed.
The global repricing of inflation expectations continues at a feverish pace in the aftermath of the Trump victory, leading to another surge in US equity futures, up 15 points or 0.7% to 2175, with Asian and European stock market all jumping.